MGRX
Mangoceuticals, Inc.1.2000
+0.0600+5.26%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
16.69MP/E (TTM)
-Basic EPS (TTM)
-2.72Dividend Yield
0%Recent Filings
10-K
FY2025 results
Mangoceuticals posted FY2025 revenue of $456K, down from $616K in FY2024, as platform migration disrupted sales momentum. Q4 saw initial respiratory patent studies complete while Dermytol prep targeted Q2 2026 rollout, but core compounded products struggled amid heavy marketing spend of $823K annually. Cash burn persisted at $5.9M operating outflow, funded by $7.3M equity raises including $2.5M December offering; working capital turned positive at $0.7M. Liquidity bolstered by $1.5M cash, yet $20.6M net loss reflects $10.8M stock comp. No annual guidance disclosed. Regulatory scrutiny on compounded drugs threatens quarterly sales ramps.
8-K
CEO options repriced; $73M suit filed
Mangoceuticals repriced CEO Jacob Cohen's outstanding options—covering 2,133,333 shares—to $0.45 per share, matching the March 16, 2026 closing price, down from originals of $16.50, $4.80, and $2.30. Board approved sans Cohen's vote. Company sued ex-consultant Clarity Ventures for over $73M in damages over failed ERP platform; built its own, boosting operations. Litigation outcome uncertain.
8-K
MGX-0024 zero mortality in trials
Mangoceuticals announced promising data on patented antiviral MGX-0024, showing zero respiratory-related mortality across ~29,000 broiler chickens in three Indian field trials versus historical 50% rates. A controlled H5N1 challenge study cut mortality by up to 60% with pre-treatment. Results position it against poultry threats. Further validation needed.
8-K
TRT sales surge 336%
8-K
Nasdaq bid price deficiency
Mangoceuticals received a Nasdaq deficiency notice on February 4, 2026, for failing Listing Rule 5550(a)(2) as its common stock bid price closed below $1.00 for 30 consecutive business days. It has 180 days until August 3, 2026, to regain compliance by sustaining $1.00+ closes for 10 straight business days. Trading continues unaffected. Stock remains listed—for now.
IPO
Employees
Sector
Industry
BRGX
BioRegenx, Inc
0.02+0.00
GDRX
GoodRx Holdings, Inc.
2.76+0.05
HIMS
Hims & Hers Health, Inc.
36.86+0.61
LFMD
LifeMD, Inc.
3.42+0.15
MAJI
Marijuana Inc.
0.05-0.02
MGRM
Monogram Technologies Inc.
6.00+0.00
MNDR
Mobile-health Network Solutions
1.08+0.02
MRMD
MariMed Inc.
0.12+0.01
TDOC
Teladoc Health, Inc.
7.41+0.07
WGRX
Wellgistics Health, Inc.
0.54-0.04